ClinicalTrials.gg
RecruitingNCT07379684Updated Nov 2, 2026

A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or Cutaneous Abscess

A Phase 1 interventional study of Amicidin-β topical solution - 15 mL and Amicidin-β topical solution - 50 mL in Surgical Wound Infection, Traumatic Wound Infection and Cutaneous Abscess, sponsored by Macro Biologics, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Macro Biologics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 2, 2026Start date movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 202 studies in Surgical Wound Infection with a site in United States — 31 open to participants now, 34 under way, 4 of them phase 3. Surgical Wound Infection · United States.

Planned enrollment
134th of 177
44 · median 208
Started
2026
with 6 others
Phase 1
10 of 202
2 open now
Primary completion
2027-02
later than 16 of 33 live
Registered
196th of 202
by date

Among the 202 studies in Surgical Wound Infection with a site in United States, this one is the 134th largest by planned enrollment of the 177 interventional ones that give a count, is one of 7 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 16 of the 33 other live ones, and was the 196th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

31 of the 202 studies in Surgical Wound Infection with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Surgical Wound Infection with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into contaminated or infected surgical or traumatic wounds or cutaneous abscess during a surgical procedure. The main questions it aims to answer are:

  1. Is Amicidin-β topical solution safe to test in larger clinical trials?
  2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application?
  3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive either standard of care alone, or standard of care with intrawound Amicidin-β topical solution for the management of their wound infection. Researchers will compare these two groups (standard of care alone to standard of care with Amicidin-β topical solution) to see if there are any study drug-related adverse effects.
Read the detailed description

This is a Standard of Care (SOC)- controlled study of approximately 44 patients divided into three sequential cohorts of 8, 12, and 24 patients. Within each sequential cohort, patients will be randomized to SOC only or to SOC plus Amicidin-β topical solution in a 1:3 ratio.

03

Conditions studied

  • Surgical Wound Infection
  • Traumatic Wound Infection
  • Cutaneous Abscess

Keywords

  • Contaminated or Infected Surgical Wound
  • Contaminated or Infected Traumatic Wound
  • Contaminated or Infected Cutaneous Abscess
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Surgical or traumatic wound ≤90 days old or a cutaneous abscess that is:

    1. ≥3 cm in length of longest dimension;
    2. requires an interventional procedure, such as opening, incision, drainage, irrigation, and/or debridement; and
    3. is anticipated by the Investigator to be Class III (contaminated) or Class IV (dirty/infected).
  • If female of , must have been practicing an acceptable method of as judged by the Investigator for at least one month prior to enrollment.
  • Females of childbearing potential must agree that for the entire duration of the study (about 30 days), they will either practice true abstinence consistent with their preferred and usual lifestyle, or use double contraceptive methods.

Main Exclusion Criteria:

Patients with any of the following will be excluded:

  • Wound or cutaneous abscess associated with surrounding cellulitis extending ≥10 cm from the wound edge;
  • Suspected necrotizing fasciitis or gangrenous ulcer. Necrotizing fasciitis is understood to be a rare severe form of necrotizing soft tissue infection (NSTI). Patients with limited tissue necrosis surrounding an infection or with diagnosis of NSTI that is not considered by the Investigator to be severe and rapidly progressive are eligible. If necrotizing fasciitis is confirmed during the interventional procedure, the patient should be withdrawn immediately and patient should be treated with SoC;
  • Multiple wounds at different sites determined to be Class III (contaminated) or Class IV (dirty/infected);
  • Wound infection overlying bone fracture, with radiological evidence of non-union. A Class III or Class IV wound over a healed bone fracture is not exclusionary;
  • Wound infection with open peritoneal cavity;
  • Wound with infection extending to an organ space;
  • Wound with infection extending to implanted surgical hardware or protesis. Note: surgical drains and packing are permitted;
  • Wound or cutaneous abscess on head and neck;
  • Wound or cutaneous abscess on hands or feet;
  • Wound or cutaneous abscess involving burn injury;
  • Suspected or confirmed osteomyelitis or septic arthritis;
  • Wound contamination or infection or cutaneous abscess known or suspected to be caused by fungal (other than Candida spp.) or by mycobacterial organisms;
  • Wound or cutaneous abscess on a lower extremity that also has a neuropathic or diabetic foot ulcer or a previous diagnosis of moderate to severe chronic venous insufficiency;
  • Patient requires long-term supplemental O2 or mechanical ventilation. Patients requiring short-term supplemental O2 prior to, during, or post-interventional procedure are eligible;
  • Pulse Oximetry (SpO2) reading of ≤ 92% on room air (confirmed by two additional readings ≤92% over 15 min). At geographic locations of high altitude, a lower SpO2 limit (e.g., ≤ 91%) may be used at Investigator's discretion;
  • Uncontrolled insulin-dependent diabetes mellitus or diagnosis of diabetes mellitus which, in the opinion of the Investigator, is poorly controlled;
  • Profound (e.g., induction therapy);
  • Diagnosis of genetic hypercoagulable state (e.g., anti-phospholipid syndrome, Factor V Leiden, prothrombin gene mutation);
  • History in the last 12 months of myocardial infarction, coronary artery disease requiring interventional treatment (e.g., angioplasty / stenting, bypass), stroke, , deep vein thrombosis, pulmonary embolism, or antithrombotic therapy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    SOC + Amicidin-β topical solution - 15 mL

    In addition to Standard of Care (SOC), patients will receive Amicidin-β topical solution - 15 mL immediately prior to wound closure/dressing, with rinsing out with saline.

    Drug: Amicidin-β topical solution - 15 mL · Drug: Standard of Care (SOC)

  • Experimental
    SOC + Amicidin-β topical solution - 50 mL - Scheme 1

    In addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, with rinsing out with saline

    Drug: Amicidin-β topical solution - 50 mL · Drug: Standard of Care (SOC)

  • Experimental
    SOC + Amicidin-β topical solution - 50 mL - Scheme 2

    In addition to Standard of Care (SOC), patients will be receive Amicidin-β topical solution - 50 mL immediately prior to wound closure/dressing, without rinsing out with saline

    Drug: Amicidin-β topical solution - 50 mL · Drug: Standard of Care (SOC)

  • Active comparator
    SOC

    Patients will receive Standard of Care (SOC) only

    Drug: Standard of Care (SOC)

Interventions

  • DrugAmicidin-β topical solution - 15 mL

    Amicidin-β topical solution for local administration - 15 mL

  • DrugAmicidin-β topical solution - 50 mL

    Amicidin-β topical solution for local administration - 50 mL

  • DrugStandard of Care (SOC)

    Per institutional Standard Of Care

06

What researchers measure

Primary outcomes

  1. Overall comparison of treatment emergent adverse events (TEAES) of combined SOC + Amicidin-β topical solution recipients to SOC only recipients across 3 cohorts.

    Time frame: From Day 1 to Day 30

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) by severity according to the study protocol.

    Time frame: From Day 1 to Day 30

  2. Measurement of systemic absorption of Amicidin-β recipients.

    Systemic absorption will be assessed by single molecule array (Simoa) immunoassay measurements of patient plasma.

    Time frame: From Day 1 to Day 3

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 30, 2026
StartActual
Aug 18, 2026was Sep 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 30, 2026→Aug 18, 2026 (actual)
Nov 2, 2026
Eligibility
Maximum age 79 Years→none; 9 criteria edited, 12 added, 13 removed
What changed in the criteria
  • RemovedBody Mass Index between 18.5 kg/square meter and 39.9kg/square meter
  • RemovedSurgical or traumatic wound determined by the Investigator to be infected within 90 days of surgery or trauma, with longest dimension between 3 and 15 cm. The diagnosis should include one or more of the following signs or symptoms:
  • RemovedPurulent drainage
  • RemovedErythema
  • RemovedSurrounding induration
  • RemovedFever or localized heat surrounding the wound
  • RemovedReported localized pain or localized tenderness on examination
  • AddedSurgical or traumatic wound ≤90 days old or a cutaneous abscess that is:
  • Added≥3 cm in length of longest dimension;
  • EditedInfected surgical or traumatic wound that is determined by the Investigator to requiredrequires an interventional procedure, such as opening, incision, drainage, irrigation, and/or debridement.; and
  • Addedis anticipated by the Investigator to be Class III (contaminated) or Class IV (dirty/infected).
  • EditedSurgicalWound or traumatic woundcutaneous abscess associated with surrounding cellulitis extending ≥10 cm from the wound edge;
  • RemovedConfirmed necrotizing fasciitis or gangrenous ulcer
  • RemovedMultiple surgical or traumatic wound infections at different sites
  • AddedSuspected necrotizing fasciitis or gangrenous ulcer. Necrotizing fasciitis is understood to be a rare severe form of necrotizing soft tissue infection (NSTI). Patients with limited tissue necrosis surrounding an infection or with diagnosis of NSTI that is not considered by the Investigator to be severe and rapidly progressive are eligible. If necrotizing fasciitis is confirmed during the interventional procedure, the patient should be withdrawn immediately and patient should be treated with SoC;
  • AddedMultiple wounds at different sites determined to be Class III (contaminated) or Class IV (dirty/infected);
  • EditedSurgical or traumatic woundWound infection overlying bone fracture, with radiological evidence of non-union. A Class III or Class IV wound over a healed bone fracture is not exclusionary;
  • EditedSurgical or traumatic woundWound infection with open peritoneal cavity;
  • EditedSurgical or traumatic woundWound with infection extending to an organ space;
  • EditedSurgical or traumatic woundWound with infection extending to implanted surgical hardware or protesis. Note: surgical drains and packing are permitted;
  • RemovedSurgical or traumatic wound infection involving head and neck
  • AddedWound or cutaneous abscess on head and neck;
  • AddedWound or cutaneous abscess on hands or feet;
  • EditedSurgicalWound or traumatic wound infectioncutaneous abscess involving burn injury;
  • EditedSurgicalWound contamination or traumatic wound infectioninfection or cutaneous abscess known or suspected to be caused by fungal (other than Candida spp.) or by mycobacterial organisms;
  • EditedWound with diagnosis ofor cutaneous abscess on a lower extremity that also has a neuropathic or diabetic foot ulcer or a previous diagnosis of moderate to severe chronic venous insufficiency of a lower extremity in patients with an infected surgical to traumatic wound of the lower extremity;
  • RemovedWound due to malignancy
  • RemovedAntibiotic therapy for an infection other than the surgical or traumatic wound infection
  • RemovedPatient requires supplemental O2 or mechanical ventilation
  • AddedPatient requires long-term supplemental O2 or mechanical ventilation. Patients requiring short-term supplemental O2 prior to, during, or post-interventional procedure are eligible;
  • AddedUncontrolled insulin-dependent diabetes mellitus or diagnosis of diabetes mellitus which, in the opinion of the Investigator, is poorly controlled;
  • AddedProfound immunosuppression (e.g., induction therapy);
  • AddedDiagnosis of genetic hypercoagulable state (e.g., anti-phospholipid syndrome, Factor V Leiden, prothrombin gene mutation);
  • AddedHistory in the last 12 months of myocardial infarction, coronary artery disease requiring interventional treatment (e.g., angioplasty / stenting, bypass), stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism, or antithrombotic therapy.
Nov 2, 2026
Title
A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound Infectionsor Cutaneous Abscess
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Sep 30, 2026→Aug 18, 2026 (now actual)
    Eligibility Maximum age 79 Years→none; 9 criteria edited, 12 added, 13 removed
    What changed in the criteria
    • RemovedBody Mass Index between 18.5 kg/square meter and 39.9kg/square meter
    • RemovedSurgical or traumatic wound determined by the Investigator to be infected within 90 days of surgery or trauma, with longest dimension between 3 and 15 cm. The diagnosis should include one or more of the following signs or symptoms:
    • RemovedPurulent drainage
    • RemovedErythema
    • RemovedSurrounding induration
    • RemovedFever or localized heat surrounding the wound
    • RemovedReported localized pain or localized tenderness on examination
    • AddedSurgical or traumatic wound ≤90 days old or a cutaneous abscess that is:
    • Added≥3 cm in length of longest dimension;
    • EditedInfected surgical or traumatic wound that is determined by the Investigator to requiredrequires an interventional procedure, such as opening, incision, drainage, irrigation, and/or debridement.; and
    • Addedis anticipated by the Investigator to be Class III (contaminated) or Class IV (dirty/infected).
    • EditedSurgicalWound or traumatic woundcutaneous abscess associated with surrounding cellulitis extending ≥10 cm from the wound edge;
    • RemovedConfirmed necrotizing fasciitis or gangrenous ulcer
    • RemovedMultiple surgical or traumatic wound infections at different sites
    • AddedSuspected necrotizing fasciitis or gangrenous ulcer. Necrotizing fasciitis is understood to be a rare severe form of necrotizing soft tissue infection (NSTI). Patients with limited tissue necrosis surrounding an infection or with diagnosis of NSTI that is not considered by the Investigator to be severe and rapidly progressive are eligible. If necrotizing fasciitis is confirmed during the interventional procedure, the patient should be withdrawn immediately and patient should be treated with SoC;
    • AddedMultiple wounds at different sites determined to be Class III (contaminated) or Class IV (dirty/infected);
    • EditedSurgical or traumatic woundWound infection overlying bone fracture, with radiological evidence of non-union. A Class III or Class IV wound over a healed bone fracture is not exclusionary;
    • EditedSurgical or traumatic woundWound infection with open peritoneal cavity;
    • EditedSurgical or traumatic woundWound with infection extending to an organ space;
    • EditedSurgical or traumatic woundWound with infection extending to implanted surgical hardware or protesis. Note: surgical drains and packing are permitted;
    • RemovedSurgical or traumatic wound infection involving head and neck
    • AddedWound or cutaneous abscess on head and neck;
    • AddedWound or cutaneous abscess on hands or feet;
    • EditedSurgicalWound or traumatic wound infectioncutaneous abscess involving burn injury;
    • EditedSurgicalWound contamination or traumatic wound infectioninfection or cutaneous abscess known or suspected to be caused by fungal (other than Candida spp.) or by mycobacterial organisms;
    • EditedWound with diagnosis ofor cutaneous abscess on a lower extremity that also has a neuropathic or diabetic foot ulcer or a previous diagnosis of moderate to severe chronic venous insufficiency of a lower extremity in patients with an infected surgical to traumatic wound of the lower extremity;
    • RemovedWound due to malignancy
    • RemovedAntibiotic therapy for an infection other than the surgical or traumatic wound infection
    • RemovedPatient requires supplemental O2 or mechanical ventilation
    • AddedPatient requires long-term supplemental O2 or mechanical ventilation. Patients requiring short-term supplemental O2 prior to, during, or post-interventional procedure are eligible;
    • AddedUncontrolled insulin-dependent diabetes mellitus or diagnosis of diabetes mellitus which, in the opinion of the Investigator, is poorly controlled;
    • AddedProfound immunosuppression (e.g., induction therapy);
    • AddedDiagnosis of genetic hypercoagulable state (e.g., anti-phospholipid syndrome, Factor V Leiden, prothrombin gene mutation);
    • AddedHistory in the last 12 months of myocardial infarction, coronary artery disease requiring interventional treatment (e.g., angioplasty / stenting, bypass), stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism, or antithrombotic therapy.
    Title A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound Infectionsor Cutaneous Abscess
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07379684
Lead sponsor
Macro Biologics, Inc.
Collaborators
Biomedical Advanced Research and Development Authority, Novo Nordisk Foundation, Global Antimicrobial Resistance Innovation Fund-(GAMRIF), US NIH Grant/Contract Award Number: HHS/BARDA OTA No. 75A50122C00028, Wellcome Trust 224842/Z/21/Z, Germany's Federal Ministry of Education and Research (BMBF) Agreement Dated 1/30/23, UK Secretary of State for Health and Social Care ("DHSC"), Agreement dated 02/28/2023
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Aug 18, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Daniel J Gowen-Huang, MBA
Contact
dgowenhuang@macrobiologics.com
(323) 717-0302
Michael P Bevilacqua, MD, PhD
Contact
mpb@macrobiologics.com
(303) 881-5169

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion